Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
Critical Reviews in Oncology/Hematology|January 10, 2020
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelinesF Passiglia, S Pilotto, F Facchinetti, et al.Critical Reviews in Oncology/Hematology|February 17, 2020
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelinesF Passiglia, L Bertolaccini, M Del Re, et al.Journal of Lipid Research|February 4, 2003
Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigenKazuko Kobayashi, Makoto Kishi, Tatsuya Atsumi, et al.Annals of the Rheumatic Diseases|November 18, 2004
Association of HLA-DM polymorphism with the production of antiphospholipid antibodiesM L Sanchez, K Katsumata, T Atsumi, et al.Bioorganic & Medicinal Chemistry|January 30, 1999
Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonistsK D Robarge, M S Dina, T C Somers, et al.Neuropharmacology|March 27, 2018
The reduction in glutamate release is predictive of cognitive and emotional alterations that are corrected by the positive modulator of AMPA receptors S 47445 in perinatal stressed ratsS Morley-Fletcher, A R Zuena, J Mairesse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade GliomaPatrick Y Wen, Timothy F Cloughesy, Alan G Olivero, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.The Lancet. Haematology|August 30, 2016
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialHannah Cohen, Beverley J Hunt, Maria Efthymiou, et al.Lupus|February 10, 2011
'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010M L Bertolaccini, O Amengual, T Atsumi, et al.Pageof 12